藥明巨諾-B(2126.HK)大漲超13% CAR-T產品瑞基奧侖賽注射液正式獲批
格隆匯9月6日丨延續近日漲勢,藥明巨諾-B(2126.HK)今日盤中加速上漲,一度漲超13%至20.2港元,為連續第四日上漲,股價創8月13日以來新高,市值逾80億港元。藥明巨諾上週五公吿,CAR-T療法產品“瑞基侖賽注射液”(JWCAR029)獲批上市,用於經過二線或以上全身性治療後成人患者的復發或難治性大B細胞淋巴瘤。瑞基侖賽是國內第2款獲批上市的CAR-T產品,同時也是國內首個獲批的1類CAR-T 、全球第6款獲批上市的CAR-T產品。據悉,藥明巨諾的瑞基奧侖賽注射液是中國目前唯一一款同時獲得重大新藥創制專項、新藥上市申請優先審評資格(r/r LBCL)、及突破性治療藥物認定(濾泡性淋巴瘤)等三項殊榮的已獲批CAR-T產品。迄今為止,已經有100多位患者在臨牀研究中接受了瑞基奧侖賽的治療,使其成為中國擁有最多臨牀經驗的靶向CD19的CAR-T產品。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.